Overview and Current Status of Alzheimer’s Disease in Bangladesh

Md. Rashidur Rahman*, Afsana Tajmim, Mohammad Ali and Mostakim Sharif

Department of Pharmacy, Jessore University of Science and Technology, Jessore, Bangladesh

Accepted 16 May 2017

Abstract. Alzheimer’s disease (AD) is a complex neurological disorder with economic, social, and medical burdens which is acknowledged as leading cause of dementia marked by the accumulation and aggregation of amyloid-β peptide and phosphorylated tau (p-tau) protein and concomitant dementia, neuron loss and brain atrophy. AD is the most prevalent neurodegenerative brain disorder with sporadic etiology, except for a small fraction of cases with familial inheritance where familial forms of AD are correlated to mutations in three functionally related genes: the amyloid-β protein precursor and presenilins 1 and 2, two key γ-secretase components. The common clinical features of AD are memory impairment that interrupts daily life, difficulty in accomplishing usual tasks, confusion with time or place, trouble understanding visual images and spatial relationships. Age is the most significant risk factor for AD, whereas other risk factors correlated with AD are hypercholesterolemia, hypertension, atherosclerosis, coronary heart disease, smoking, obesity, and diabetes. Despite decades of research, there is no satisfying therapy which will terminate the advancement of AD by acting on the origin of the disease process, whereas currently available therapeutics only provide symptomatic relief but fail to attain a definite cure and prevention. This review also represents the current status of AD in Bangladesh.

Keywords: Alzheimer’s disease, age, risk factors, diagnosis, genes

INTRODUCTION

Alzheimer’s disease (AD) is a multifactorial neurodegenerative brain disorder in which approximately 5.3 million people in the United States, including almost half of the population at 85 years and older have affected and it has become a devastating condition with a huge societal impact, both in terms of financial cost and the progression of number of older people [1, 2]. It has become the only one of the top ten causes-of-death with unknown genetic causes as well as no specified diagnosis and disease-altering treatments [3]. Neuritic plaques containing amyloid-β peptide (Aβ42) and neurofibrillary tangles composed of hyperphosphorylated tau are considered as microscopic hallmarks of AD [4]. AD results from a combination of genetic, environmental and lifestyle factors [5]. Although, at present there is no permanent known cure of AD, current treatment advances are designed for assisting people to maintain mental function, manage behavioral symptoms, and slow or delay the symptoms of disease by targeting specific genetic, molecular, and cellular mechanisms so that the actual underlying cause of the disease can be prevented [1]. The clinical presentation of AD is heterogeneous and insidious, whereas the psychological and financial effects of AD on caregivers and family members are significant. In this review, we study clinical features of AD, various risk factors; several genes associated with AD, available diagnosis process, pathophysiology of AD, treatment of AD. We also emphasize on the recent advances on the
molecular pathogenesis and the implications for the development of treatment and of new methods for early diagnosis, taking into account existing observations.

**CLINICAL FEATURE**

AD is an irreversible, progressive brain disorder which slowly demolishes memory and thinking skills and, eventually, the power of accomplishing the simplest tasks [1]. Being a neurodegenerative disease [6], AD slowly and progressively declines brain cells. As it is the most common form of dementia, it affects 60–65% percent of people with dementia worldwide [7–9]. It is named after German neurologist Alois Alzheimer, who in 1907 first recognized the symptoms as well as the neuropathological characteristics of the disease, such as amyloid plaques as well as tangles in the brain [6]. AD declines memory and cognitive function resulting confusion, alteration of mood and disorientation in time and space. In most people with AD, symptoms first come along in their mid-60s [8–10] though it is neither infectious nor contagious. Again, AD can be either sporadic or familial [8] where sporadic AD can affect adults at any age usually showing effects after age 65 and is well-known as the most common form of AD [8–13]. The reason of occurring very uncommon form of AD named familial AD is mutation in one of several genes [7, 14, 15].

Dementia is a syndrome which is characterized as the progressive deterioration of cortical functioning including language, judgment, comprehension, memory, thinking and learning [16–18]. The course of dementia will differ from person to person and is associated with a range of factors including the subtype of dementia, physical health, lifestyle factors and the social supports of the person with the disease [8]. When AD progresses, the person’s ability to accomplish roles of daily living such as shopping or managing finances will be hampered, which suggests the need of personal assistance to undertake even simple activities for that person. The Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for AD require the presence of progressive deficits in at least two cognitive domains, one of which should be memory, which are not related to any other disease process [10]. The cognitive deficits must represent a change from a previous state of normal functioning. These changes must be distinguished from acute or subacute confusional states or delirium (emietabolic encephalopathy). The recent National Institute on Aging/Alzheimer’s Association criteria for dementia requires impairments in two cognitive domains for the diagnosis of dementia, not necessarily in memory functions [8, 11, 12]. The clinical features of AD differ among individuals where the most common initial feature is demonstrated as significant deterioration to recollect new information. This memory impairment occurs because the first neurons to malfunction and die are usually neurons in brain regions engaged in generating new memories [8, 13, 15, 16]. As neurons in other parts of the brain malfunction and die, individuals experience other difficulties.

Overall, the common clinical features of AD are memory impairment that interrupts daily life, challenges in designing or resolving problems, difficulty in accomplishing usual tasks at home, at work or at leisure, confusion with time or place, trouble understanding visual images and spatial relationships, new problems with words in speaking or writing [8].

**RISK FACTOR**

**Age**

Age is the most significant risk factor for AD where the incidence of AD in men and women increases robustly with age [19, 20]. The International Alzheimer’s Disease Report estimates that 47 million people worldwide are living with AD in 2015, and this is estimated to increase to 131 million people by 2050 [21]. After the age of 65, the lifetime risk of AD is one in six for women (16.7%), whereas it is one in eleven for men (9.1%) [22].

**Obesity/metabolic syndrome**

Relationship between AD and obesity suggests an up to 40% increased risk for obese individuals in some studies, [23–26] others have observed no correlation [27–29]. Weight loss and low body mass index are significantly correlated with elevated risk of AD in older adults, whereas a higher body mass index may be protective at advanced ages [23, 30–32].

**Family history of Alzheimer’s disease**

Family history of AD may play crucial role in the occurrence and advancement of AD. The persons whose parents or siblings are the patients of AD are
more susceptible to AD than a person do not have family history of AD [33–35]. The exact relationship between the elevated risk of AD and family history of AD is not fully recognized through existing research.

**Smoking**

Early onset of AD is correlated with smoking which is considered as a modifiable risk factor for AD estimating to account for 4.7 million AD cases worldwide. Numerous studies have observed that smoking has been associated with both increased and decreased risk for AD. But, smoking during lifetime is linked with at least a 1.7 times (70%) greater risk for AD, and the risk markedly elevates with greater cumulative smoking exposure [36].

**General anesthesia and AD**

Several studies have reported the preclinical manifestation for the possible role of general anesthesia in the advancement of AD processes in cell culture or animal models. Current demonstration suggests the correlation between exposure to volatile general anesthesia and AD pathogenesis in transgenic mouse models [37, 38], whereas the evolution of tauopathy [37] and Aβ processes linked with AD have also been detected in animals exposed to general anesthesia [37].

**Diet**

Numerous research studies have been demonstrated that dietary components may play crucial role in the progression of AD risk observing in both human and animal models. Cognitive impairment in humans, elevated levels of Aβ and tau pathology in rodents which are the predictors of AD pathogenesis are correlated with the high sucrose and fructose contents of Western diets [39–42] whereas trans and saturated fatty acids are linked with higher risk of AD and mild cognitive impairment [43, 44]. Trans and saturated fatty acids are shown to exhibit high levels of Aβ by another rodent experiment [45, 46]. Again, diet with induced oleic acid and reduced fat was found to decrease Aβ levels and pathology in transgenic mice [47]. Various observations have been suggested that Aβ levels decreases significantly with diets containing high omega 3 polyunsaturated fatty acids [48–51].

**Others**

Cardiovascular disease, social and cognitive engagement, traumatic brain injury, down syndrome etc. are also suspected as risk factors of AD but no significant research has been established to demonstrate their relationship with AD [52–64].

**GENETIC FACTOR**

**Apolipoprotein E (APOE)**

Apolipoprotein E (APOE) is one of the strongest heritable risk factor for late onset of AD which is located on the proximal long arm of 19th chromosome i.e., at chromosome 19q13.2 which encodes a pleiotropic glycoprotein [8–10, 65–67]. It is well-known essential brain apolipoprotein which is secreted by astrocytes [68–71]. In 1991, the relationship between APOE and AD was first introduced [65] and later it was affirmed in 1993 through studies of an association between the APOE ε4 allele and AD risk [6, 7, 66, 72]. Being distributed in liver, brain, and macrophages [11, 73], the APOE gene exists as three polymorphic alleles (ε2, ε3, and ε4), where the APOE ε3 allele is the most common (77%), ε2 allele is the least common (8%) [74, 75]. Individuals having the ε4 allele have higher risk of AD in comparison with subjects carrying the more common ε3 allele, whereas the ε2 allele decreases risk [76, 77]. APOE ε4 elevates risk in familial and sporadic early and late-onset AD [18] with dose-dependent effect on age at onset [66, 78].

**AβPP**

Amyloid-β protein precursor (AβPP) is a type-l transmembrane neuronal protein which is situated at chromosome 21q21 [79–82]. It acts like a signal-transduction receptor and is distributed in many tissues and intensified in the synapses of neurons [83, 84]. Firstly, AβPP is made in the endoplasmic reticulum, then post transcriptionally modulation occurs in the Golgi (N- and O-linked glycosylation, sulfation, and phosphorylation), and finally, released to the cell surface via the secretory pathway and endocytosed and processed in the endosomal-lysosomal pathway from the cell surface [85, 86]. Approximately 14% of early-onset autosomal dominant cases of AD are occurred by dominant mutations in AβPP, whereas
two recessive AβPP mutations (A673V and E693D) generate early-onset AD [78].

Presenilin 1 (PSEN1) and Presenilin 2 (PSEN2)

Presenilins are major components of the atypical aspartyl protease complexes which are involved in the γ-secretase cleavage of AβPP [87]. PSEN1 and PSEN2 belong to integral membrane proteins which is composed of nine transmembrane domains with a hydrophilic intracellular loop region and located on chromosome 14q24.3 and on chromosome 1q31-q42 respectively [79, 88]. It is distributed in the cell surface, Golgi, endoplasmic reticulum, and mitochondria [89, 90].

ATP Binding Cassette Transporter 7 (ABCA7)

Being a member of ABC transporter superfamily, ABCA7 was first reported in macrophages whose location of ABCA7 is on chromosome 19p13.3. It exhibits significant roles in lipid metabolism and the phagocytosis of apoptotic cells [91–93]. Through the C1q complement pathway, ABCA7 has suspected function to modulate phagocytosis of apoptotic cells by macrophages [94]. Again, it manifests in the efflux of lipids from cells into lipoprotein particles with stimulating cholesterol efflux by inhibiting Aβ secretion in vitro [95].

AKAP9: a kinase (PRKA) anchor protein 9

Being expressed in the hippocampus, cerebellum and the cerebral cortex and encoding with a scaffold protein with physical attachment of type I protein phosphatase and cAMP-dependent protein kinase to the N-methyl-D-aspartate receptors for stimulating channel activity, AKAP9 is located on chromosome 7q21.2 [96, 97].

Bridging Integrator 1 (BIN1)

The location of BIN1 (Bridge Integrator 1 or Amphiphysin 2) is on chromosome 2 (2q14.3) which was recognized as Myc box-dependent-interacting protein 1 by interacting with Myc-box region of the MYC oncprotein encodes several splice variants [98–100]. The SNPs in BIN1 modulating risk for late onset AD were identified by genomewide association study [101, 102], whereas in aging mice, in transgenic mouse models of AD, and in persons with schizophrenia, the variation of the nature of BIN1 has been demonstrated [103, 104]. The role of BIN1 is in enhancing Clathrin-mediated endocytosis, intracellular endosome trafficking, senescence, immune response, calcium homeostasis, and caspase-independent apoptosis [105–108], whereas BIN1 has been observed to involve in phagocytosis by macrophages and attaches α-integrins to modulate the immune response [109].

CD2 Associated Protein (CD2AP)

The composition of scaffolding protein named CD2AP is 639 amino acids with molecular mass of approximately 70 kDa [110] which exhibit its activities in cytoskeletal reorganization and intracellular trafficking [111]. Being distributed in adult and fetal human tissues as an approximately 5.4kb transcript [112], it is located on chromosome 6p12 which encodes CD2 associated protein [112]. CD2AP is related in mediating vesicular trafficking to the lysosome and it is attached with proteins involved in cytoskeletal organization [113] resulting endocytosis [114, 115] and cell-cell interactions [116]. Ligand binding of CD2AP improves protein segregation, CD2 clustering, and cytoskeletal polarization [111].

Clusterin (CLU)

A stress-activated chaperone protein encoding three alternative transcripts named Clusterin (CLU) is a 75 kDa apolipoprotein which is located on chromosome 8p21.1 [117, 118]. Being distributed throughout the body, especially in the brain for exhibiting its activities in apoptosis, complement regulation, lipid transport, membrane protection, and cell-cell interactions [117], clusterin alters Aβ clearance, amyloid deposition, and neuritic toxicity and purified clusterin interacts with Aβ affecting fibril formation in vitro [119, 120]. By modulating the membrane attack complex, clusterin inhibits the inflammatory response associated with complement activation [117].

CD33

CD33 may mediate Aβ clearance and other neuroinflammatory pathways which are controlled by microglia in the brain whereas high CD33 brain expression has been associated with AD status [121].
**Ephrin Type-A Receptor 1 (EPHA1)**

In transgenic mouse models of AD, it was demonstrated that ephrin receptors were minimized in the hippocampus prior to the development of impaired object recognition and spatial memory, while low levels of Eph receptor have been recognized in postmortem hippocampal tissue from patients with incipient AD [122].

**SORL1**

Being originally recognized as an AD risk gene in candidate-based approaches [123, 124], SORL1 mediates the processing of AβPP by presenilins and the production of Aβ [125]. Recent meta-analysis of one observation has been demonstrated a significant association between clusters of polymorphisms in SORL1 and AD in both Caucasians and Asians [126].

**TREM2**

One type of transmembrane receptor protein called TREM2 is located on chromosome 6q21.1 which is expressed on myeloid cells to regulate phagocytosis and suppress inflammation reactivity [127] including microglia, monocyte-derived dendritic cells, osteoclasts, and bone-marrow-derived macrophages [128].

**Tau**

Tau is a cardinal constituent of neurofibrillary tangles which is located on chromosome 17 of the human genome expressing six isoforms of the tau protein in adult human brain [129, 130]. Tau has been found to be associated with induced oxidative stress, impaired protein-folding function in the endoplasmic reticulum, and deficient proteasome-mediated which is also linked with autophagy-mediated clearance of damaged proteins in AD [131, 132].

**Phosphatidylinositol Binding Clathrin Assembly Protein (PICALM)**

The location of the PICALM gene is on chromosome 11 (11q14.2) which is distributed in acute myeloid leukemia, acute lymphoblastic leukemia, and malignant lymphoma [133], whereas the levels of PICALM were modulated in the brain of an amyloid mouse model of AD in contrast to wild-type mice [134].

**DIAGNOSIS**

The diagnosis of AD depends on clinical features, medical history, family discussions and contemporary diagnostic tests including clinical, neurological, and psychiatric examination whereas neuropsychological testing can be recognized as a tool for getting objective signs of memory disturbances in early stages and laboratory studies, such as thyroid-function tests and serum vitamin B12, are used to explain the secondary causes of AD. But, the 2011 criteria and guidelines recommend biomarker tests for the recognition of two biomarker categories: (1) bio-markers demonstrating the level of Aβ accumulation in the brain and (2) biomarkers exhibiting that neurons in the brain are declined or actually degenerating. The proper application of theses biomarkers helps researchers to enroll individuals with the brain changes for providing treatments target [135, 136]. Various stage of the disease with various factors, like environmental factor, genetic factors, age, sex, etc., should be considered carefully to get significant results from biomarker test or combination of test [58]. For the diagnosis of AD, the elevated levels of cerebrospinal fluid (CSF) biomarkers have been detected in the combination magnetic resonance imaging (MRI) and CSF biomarkers as the diagnostic accuracy. All these are measured significantly through MRI to predict future clinical decline [135–138]. Again, these are demonstrated significantly by a multimodal classifier which firstly chooses MRI and fluorodeoxyglucose positron emission tomography (PET) regions of interest, then combines them with CSF biomarker data accurately [139]. Some methods used as diagnostic tools for the disease are MRI measurements of medial temporal lobe atrophy, PET imaging of glucose metabolism and Aβ deposits, and CSF biomarkers, but recently none of these are recommended in any consensus guidelines for diagnosis of the disease [139, 140]. To get validated diagnosis techniques, further research is needed in large prospective studies.

**PATHOPHYSIOLOGY OF ALZHEIMER’S DISEASE**

The pathophysiology of AD is depended on numerous hypotheses because of its multifactorial characteristics [141]. Various causative factors make the pathophysiology of AD more complex involving a number of processes. Numerous hypotheses
are associated with AD pathophysiology including cholinergic hypothesis, Aβ hypothesis, tau hypothesis and inflammation hypothesis [142, 143]. Two major hypotheses are correlated with AD: accumulation of protein plaques which is consisted of Aβ [144] as well as, the generation of neurofibrillary tangles linked to hyperphosphorylation of tau proteins [145]. These protein abnormalities and oxidative stress and inflammation, failure of synaptic function, depletion of neurotransmitters and eventual cell death [145] are associated with the pathophysiology of AD. Recently it has been recognized that the most commonly employed Aβ hypotheses which is considered as triumph for the last two decades, does not account for the complicated pathophysiology of this crippling disorder [146]. The function of Aβ oligomers in synaptic impairment has been reported significantly in current observations which indicates that these are primarily the only one among several other signals declining the integrity of brain functions [143, 147, 148]. Again, the generation of amyloid plaques arising in the later age which becomes prominent to be rather late event [149].

TREATMENT

**Anti-amyloid therapies**

Acting on Aβ aggregates which are well-known as amyloid plaques is the main focus of anti-amyloid therapies for the treatment of AD.

**Drugs to reduce Aβ production**

β-secretase inhibitors: The outcome of BACE inhibitor is in significant reduced levels of Aβ_{40} and Aβ_{42} in brain of AβPP transgenic mice and elevated levels of soluble AβPPβ, soluble AβPPα secretion whereas β-secretase inhibitors betterment in cognition can be attained which in future may worsen with the advancing age [150–152].

γ secretase inhibitors: Semagacestat (LY-450139), MK-0752, E-2012BMS-708163, PF-3084014, Begacestat (GSI-953), and NIC5-15 are found in various clinical trials to provide γ-secretase inhibiting activity, whereas Semagacestat has been observed to minimize Aβ concentrations in plasma and Aβ production in the central nervous system [153–155]. Ibuprofen, Indomethacin, and Sulindac sulfide which are popular subsets of non-steroidal anti-inflammatory drugs firstly attach to AβPP, then reduce Aβ_{1-40} and Aβ_{1-42} production with increased generation of Aβ_{1-38} fragments for exhibiting their activity as γ-secretase modulators [156].

α-secretase modulators: Agonists of muscarinic, glutamate, statins, serotonin, oestrogens, and testosterone and protein kinase C activators are popular α-secretase modulator but their application in the treatment of AD is not well-understood [157].

**Drugs interfering with Aβ aggregation**

Stemazole, curcumin, SK-PC-B70M, T-817 MA etc. have been demonstrated to provide possess therapeutic potential for the treatment of AD [158–162].

**Metal chelators**

In the pathogenesis of AD, metals have been assumed to act as key-regulator in the treatment of AD, among them that Zn/Cu-selective chelators significantly elevate the solubilization of Aβ deposits in AD brains. [163–165].

**Enzyme mediated Aβ degradation**

Neprylisin, insulin degrading enzyme, plasmin, endothelin converting enzyme 1 and 2, and angiotensin-converting enzyme, etc. have been shown to possess their abilities of degrading Aβ peptide [166].

**Therapeutic clearance of Aβ**

**Immunotherapy-mediated Aβ clearance**

Immunotherapy mediated Aβ clearance can be attained through active and passive immunization [167], whereas active and passive Aβ immunotherapy in AD Tg mice has been observed to minimize cerebral Aβ by ameliorating cognition [168]. Active immunization with anti-Aβ has been shown to elevate amyloid plaque clearance reducing plaque-associated pathology, CSF tau level and slowing patient’s cognitive decline [169–172]. Again, withdrawal of amyloid plaques and elevation of behavioral performance in AD mice can be accomplished by its vaccination with HSV amplicons showing Aβ and interleukin-4 expression [173].

**Targeting tau phosphorylation**

Targeting hyperphosphorylated tau is an attractive approach because various phospho-tau epitopes are selectively and specifically correlated with AD pathology. Tau phosphorylation has gained importance in AD leading to microtubule instability.
Inhibition of glycogen synthase kinase 3 (GSK3) and cyclin dependent kinase 5 (CDK5), primary enzymes affecting tau phosphorylation enzymes may prevent tau phosphorylation. Both lithium and roscovitine have been reported to inhibit the actions on these kinases, whereas both lithium and valproate which are active against GSK3β can diminish tau pathology in transgenic mice [174–177]. Recently, an irreversible inhibitor of GSK3β called Tideglusib (NP031112) and other small molecule inhibitors of GSK3 like SB216763, SRN-003-556 [178] and CHIR-98014 [179] are being studied to observe their supposed prominent role in the treatment of AD.

**Herbal supplements**

Herbal supplements which can be used in the treatment of AD are *Panax ginseng*, *Ginkgo biloba* (EGb761), *Withania somnifera*, *Curcuma longa* [180–188].

**Other miscellaneous therapies**

**Statins**

Treatment with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) has been suggested to promote the prevention of AD [189]. A prospective cohort study named the Sacramento Area Latino Study on Aging (SALSA) was conducted among 1789 older (≥60 years of age) Mexican American individuals from the Sacramento, CA, area without a previous diagnosis of dementia. Here, Atorvastatin, Cerivastatin, Fluvastatin, Lovastatin were used and statin users were reported about half as likely as those who did not take statins to treat dementia/cognitive impairment (hazard ratio (HR) = 0.52; 95% CI 0.34, 0.80) during a 5-year follow-up period [190]. Another prospective observational study called the AD Anti-inflammatory Prevention Trial (ADAPT) was observed among 2,233 participants. Here, elective statin use was reported to be correlated with significantly decreased risk of incident AD that remained unchanged after adjustment for age, gender, education, and APOE genotype [191]. The application of statins was been shown to be correlated with a reduced risk of AD (HR = 0.57; 95% CI 0.37 to 0.90) in comparison with those that did not take cholesterol-lowering drugs, whereas the use of non-statin cholesterol-lowering drugs was not reported to exert the same correlation. These observations are reported in the largest population-based observational study of this kind which was known as the Rotterdam Study involving 6,992 participants for a mean of 9 years [192]. In a systemic review and meta-analysis of 16 studies in qualitative synthesis and 11 in quantitative synthesis using statins named simvastatin, lovastatin, pravastatin, the researchers demonstrated that long-term data may support beneficial role for statins in the prevention of dementia [193]. Finally, a Cochrane Database systematic review and analysis of double-blind randomized placebo-controlled trials of statins in people at risk of AD and dementia conducted two trials with 26,340 participants using simvastatin, pravastatin and demonstrated that statins given to older patients at risk for vascular disease were not beneficial in preventing dementia [194]. Based on the conflicting results of these studies and insufficient evidence, statins cannot be recommended for the purpose of AD-related dementia treatment.

**Melatonin**

In experimental models of AD, it was demonstrated that melatonin is detected to exert free radical scavenging, anti-oxidative properties, anti-amyloidogenic effects, whereas it weakens tau hyperphosphorylation. All of these properties are supposed to be beneficial in the treatment of AD [195–197]. Again, serotonin which is well-known precursor of melatonin has depleted bit-by-bit and it is reported during the course of AD [198]. Numerous studies have suggested that gold nanoparticles can be beneficial for the early detection and treatment of AD [199]. Music can be a good enhancer in patients with AD and numerous studies have been conducted to demonstrate its use as an alternative non-pharmacological treatment of AD [200–202].

**CURRENT STATUS OF ALZHEIMER’S DISEASE IN BANGLADESH**

A few data are available about the number of AD patient in Bangladesh. There is no precise epidemiological data of AD in this country [203]. Here, the awareness about AD is now in primary stage. Therefore, affected patient and their family members are facing different problems continuously. The fund for conducting research on AD is limited. A lower middle income country like Bangladesh is not yet prepared for the management of AD. At present, most of the people of the country are in the young group. However, within 20–30 years there will be huge elder group people in this country. Therefore, there will
be more chances of occurrences of AD. So, it is high
time to think about the disease and its management as
a proactive manner and take necessary action in this
regard. The policy makers, health professional and
allied groups should come forward to make national
priority for AD in Bangladesh.

Smoking rate in Bangladesh

Bangladesh is one of the largest tobacco consum-
ing countries in the world [204]. It is one of the top
ten countries with high current smoking occurrence
of 44.7% among men [205]. It was found that 43.3%
of adults aged 15 years or above use some form of
tobacco in Bangladesh. [206].

Obesity levels in Bangladesh

Almost one-fifth of the Bangladeshi adult popula-
tion is overweight, according to a global study [207].
This study also said that over the last 33 years, rates
of either being overweight or obese doubled among
Bangladeshi adults but remained low among children.
Another study found that young age obesity is alarm-
ingly high and on rise amongst urban children from
wealthy families [208].

CONCLUSION

In this paper, we assess clinical features of AD,
risk and genetic factors, available diagnosis pro-
cess, the different expressions of pathophysiological
mechanisms behind AD and its management through
conventional drug therapy, including modern inves-
tigational therapeutic strategies, currently introduced
and ongoing new insights into the potential therapeu-
tic targets elaborately to figure out complicated AD
puzzle. Though numerous clinical trials are designed
to open a new door for demystifying the exact rea-
sons of AD, structural and functional influence of
various genes associated with AD, fistful information
are available in this case. There is no therapy which
will terminate the advancement of AD by affecting
the origin of disease process, whereas some avail-
able non-targeted pharmacological treatment such as
anti-inflammatory therapy, metal chelation, antioxi-
dant supplementation, epigenetic modifications can
be deleterious due to their improper usage. Choice
of inappropriate experimental design, limited pop-
ulation, population heterogeneity, improper use of
biomarker in clinical trial, incomplete reporting of
data, failure to find suitable compound and signifi-
cant treatment procedure, failure to use appropriate
dosage, etc., can be the major reasons of failure of
understanding the neuropathological features of AD
and achieving a definite therapeutic approach.

Future direction

The number of AD patient is growing day by day.
The high occurrence of AD patient is co related with
increasing rate of the life expectancy. AD is a disease
causing great sufferings to the patient and their rela-
tives and is also a growing healthcare problem with
economical as well as social consequences. There
is so far not possible to cure AD but some symp-
tomatic treatment is available. Risk factors can help
to identify high-risk individuals who might benefit
from different therapeutic outcomes. The focus of
dementia research is developing strategy to pre-
vent or delay the onset of dementia [209]. Much of
the evidence suggests that the accumulation of Aβ
and the abnormal phosphorylation of tau is a reason-
able target [210]. However, more targeted treatment
approaches are needed to be proposed.

DISCLOSURE STATEMENT

The authors have no conflicts of interest to disclose.

REFERENCES

[1] Alzheimer’s, Association (2015) Alzheimer’s disease facts
and figures. Alzheimers Dement 11, 332-384.
[2] Trojanowski JQ, Hampel H (2011) Neurodegenerative
disease biomarkers: Guideposts for disease prevention
through early diagnosis and intervention. Prog Neurobiol
95, 491-495.
[3] Ridge PG, Ebbert MT, Kauwe JS (2013) Genetics of
Alzheimer’s disease. Biomed Res Int 2013, 254954.
[4] Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer’s
disease. Lancet 368, 387-403.
[5] Petersen RC (2004) Mild cognitive impairment as a diag-
nostic entity. J Intern Med 256, 183-194.
[6] Qi C, Kivipelto M, von Strauss E (2009) Epidemiology
of Alzheimer’s disease: Occurrence, determinants, and
strategies toward intervention. Dialogues Clin Neurosci
11, 111-128.
[7] Seeher K, Withall A, Brodaty H (2011) The dementia
research mapping project-the 2010 update: Final report.
Dementia Collaborative Research Centre, University of
New South Wales, Sydney.
[8] Alzheimer’s, Association (2016) Alzheimer’s disease facts
and figures. Alzheimers Dement 12, 459-509.
[9] Draper B (2011) Understanding Alzheimer’s and other
dementias. Longueville Books, Woollahra.
factor for Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry 47, 122-127.

[39] Francis HM, Stevenson RJ (2011) Higher reported saturated fat and refined sugar intake is associated with reduced hippocampal-dependent memory and sensitivity to interceptive signals. Behav Neurosci 125, 943-955.

[40] Lakhan SE, Kirchgesner A (2013) The emerging role of dietary fructose in obesity and cognitive decline. Nutr J 12, 114.

[41] Moreira PI (2013) High-sugar diets, type 2 diabetes and Alzheimer’s disease. Curr Opin Clin Nutr Metab Care 16, 440-445.

[42] Orr ME, Salinas A, Buffenstein R, Oddo S (2014) Mannalian target of rapamycin hyperactivity mediates the detrimental effects of a high sucrose diet on Alzheimer’s disease pathology. Neurobiol Aging 35, 1233-1242.

[43] Barnard ND, Bunner AE, Agarwal U (2014) Saturated and trans fats and dementia: A systematic review. Neurobiol Aging 35, S65-S73.

[44] Morris MC, Tangney CC (2014) Dietary fat composition and dementia risk. Neurobiol Aging 35, S59-S64.

[45] Grimm MO, Rothenhaus TL, Grössen S, Burg VK, Hundsdoerfer B, Haupenthal VJ, Friess P, Kins S, Grimm HS, Hartmann T (2012) Trans fatty acids enhance amyloidogenic processing of the Alzheimer amyloid precursor protein (APP). J Nutr Biochem 23, 1214-1223.

[46] Oksman M, Livonen H, Hogyes E, Amtul Z, Penke B, Leenders I, Broersen L, Jansen D, Wiesmann M, Fang X, Broersen LM, Oksman M, Iivonen H, Hogyes E, Amtul Z, Penke B, Leenstra I, Broersen L, Lütjohann D, Hartmann T, Tanila H (2013) Omega-3 fatty acids enhance amyloidogenic processing of the Alzheimer amyloid precursor protein (APP). J Nutr Biochem 23, 1214-1223.

[47] Amtul Z, Westaway D, Cechetto DF, Rozmahel RF (2010) Oleic acid ameliorates amyloidosis in cellular and mouse models of Alzheimer’s disease. Brain Pathol 21, 321-329.

[48] Hjorth E, Zhu M, Toro VC, Veldin I, Palmblad J, Cederholm T, Freund-Levi Y, Faxen-Irving G, Wahlund LO, Basun H, Eriksdotter M, Schultzberg M (2013) Omega-3 fatty acids enhance phagocytosis of Alzheimer’s disease-related amyloid-β42 by human microglia and decrease inflammatory markers. J Alzheimers Dis 35, 697-713.

[49] Julien C, Tremblay C, Phivilay A, Berthaume L, Emond V, Julien P, Calon F (2010) High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model. Neurobiol Aging 31, 1516-1531.

[50] Lebbadi M, Julien C, Phivilay A, Tremblay C, Emond V, Kang JX, Calon F (2011) Endogenous conversion of omega-6 into omega-3 fatty acids improves neuronal health in an animal model of Alzheimer’s disease. Neurobiol Aging 35, 600-613.

[51] Wang HX, Xu W, Pei JJ (2012) Leisure activities, cognition and dementia. Biochim Biophys Acta 1822, 482-491.

[52] Karp A, Paillard-Borg S, Wang HX, Silverstein M, Winblad B, Fratiglioni L (2006) Mental, physical and social components in leisure activities equally contribute to decrease dementia risk. Dement Geriatr Cogn Disord 21, 65-73.

[53] Di Marco LY, Marzo A, Muñoz-Ruiz M, Ikram MA, Kivipelto M, Rufenacht D, Venneri A, Soininen H, Wanke I, Vantikos YA, Frangi AF (2014) Modifiable lifestyle factors in dementia: A systematic review of longitudinal observational cohort studies. J Alzheimers Dis 42, 119-135.

[54] Sharp ES, Reynolds CA, Pedersen NL, Gatz M (2010) Cognitive engagement and cognitive aging: Is openness protective? Psychol Aging 25, 60-73.

[55] Wilson RS, Boyle PA, Yu L, Barnes LL, Schneider JA, Bennett DA (2013) Life-span cognitive activity, neuropathologic burden, and cognitive aging. Neurology 81, 314-321.

[56] Hall CB, Lipton RB, Slivinski M, Katz MJ, Derby CA, Verghese J (2009) Cognitive activities delay onset of memory decline in persons who develop dementia. Neurology 73, 356-361.

[57] Wilson RS, Mendes De Leon CF, Barnes LL, Schneider JA, Bienias JL, Evans DA, Bennett DA (2002) Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA 287, 742-748.

[58] Plassman BL, Havlik RJ, Steffens DC, Helms MJ, Newman TN, Drosdick D, Phillips C, Gau BA, Welsh-Bohmer KA, Burke JR, Guralnik JM, Breitner JC (2000) Documented head injury in early adulthood and risk of Alzheimer’s disease and other dementias. Neurology 55, 1158-1166.

[59] Smith DH, Johnson VE, Stewart W (2013) Chronic neuropathologies of single and repetitive TBI: Substrates of dementia? Nat Rev Neurol 9, 211-221.

[60] Lehman EJ, Heij MJ, Baron SL, Gersic CM (2012) Neurodegenerative causes of death among retired National Football League players. Neurology 79, 1970-1974.

[61] McKee AC, Stein TD, Nowinski CJ, Stein TD, Alvarez VE, Daneshvar DH, Lee HS, Wojtowicz SM, Hall G, Baugh CM, Riley DO, Kubilus CA, Cromptor KA, Jacobs MA, Martin BR, Abraham CR, Ikezu T, Reichard RR, Wolozin BL, Budson AE, Goldstein LE, Kowlall NW, Cantu RC (2013) The spectrum of disease in chronic traumatic encephalopathy. Brain 136, 43-64.

[62] Monti JM, Voss MW, Pence A, McAuley E, Kramer AF, Cohen NJ (2013) History of mild traumatic brain injury is associated with deficits in relational memory, reduced hippocampal volume, and less neural activity later in life. Front Aging Neurosci 5, 41.

[63] Lott IT, Dierssen M (2010) Cognitive deficits and associated neurological complications in individuals with Down’s syndrome. Lancet Neurol 9, 623-633.

[64] Karch CM, Cruchaga C, Goate AM (2014) Alzheimer’s disease genetics: From the bench to the clinic. Neuron 83, 11-26.

[65] Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261, 921-923.

[66] Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD (1993) Binding of human apolipoprotein E to synthetic amyloid beta peptide: Isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A 90, 8098-8102.

[67] Talwar P, Sinha J, Grover S, Agarwal R, Kushwaha S, Srivastava MV, Kukreti R (2016) Meta-analysis of apolipoprotein E levels in the cerebrospinal fluid of patients with Alzheimer’s disease. J Neurol Sci 360, 179-187.
[69] Mahley RW, Weisgraber KH, Huang Y (2006) Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer’s disease. *Proc Natl Acad Sci U S A* **103**, 5644-5651.

[70] Huang Y, Weisgraber KH, Macke L, Mahley RW (2004) Apolipoprotein E: Diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer’s disease. *J Mol Neurosci* **23**, 189-204.

[71] Karch CM, Goate AM (2015) Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. *Biol Psychiatry* **77**, 43-51.

[72] Pericak-Vance MA, Bebout JL, Gaskell PC Jr, Yamaoka LH, Hung WY, Alberts MJ, Walker AP, Bartlett RJ, Haynes CA, Welsh KA, Earl NL, Heyman A, Clark CM, Roses AD (1991) Linkage studies in familial Alzheimer disease: Evidence for chromosome 19 linkage. *Am J Hum Genet* **48**, 1034-1050.

[73] Siest G, Pillot T, Régis-Bailly A, Leininger-Muller M, Muller-Hill B (1987) The precursor of Alzheimer’s disease. *Science* **235**, 622-630.

[74] Kanekiyo T, Xu H, Bu G (2014) ApoE and Aβ in Alzheimer’s disease: Accidental encounters or partners? *Neuron* **81**, 740-754.

[75] Bu G (2009) Apolipoprotein E and its receptors in Alzheimer’s disease: Pathways, pathogenesis and therapy. *Nat Rev Neurosci* **10**, 333-344.

[76] Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. *Nat Rev Neurol* **9**, 106-118.

[77] Guerreiro RJ, Gustafsson DR, Hardy J (2012) The genetic architecture of Alzheimer’s disease: Beyond Aβ: PSENs and APOE. *Neurobiol Aging* **33**, 437-456.

[78] Goldgaber D, Lerman MI, McBride OW, Saffiotti U, Gajdusek DC (1987) Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer’s disease. *Science* **235**, 877-880.

[79] Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuth K, Müller-Hill B (1987) The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. *Nature* **325**, 733-736.

[80] Robukis NK, Wisniewski HM, Jenkins EC, Devine-Gage EA, Houck GE, Yao XL, Ramakrishna N, Wolfe G, Silverman WP, Brown WT (1987) Chromosome 21q21 sublocalisation of gene encoding beta-amyloid peptide in cerebral vessels and neuritic (senile) plaques of people with Alzheimer disease and Down syndrome. *Lancet* **1**, 384-385.

[81] Tanzi RE, Gusella JF, Watkins PC, Bruns GA, St George-Hyslop P, Van Keuren ML, Patterson D, Pagan S, Kurnit DM, Neve RL (1987) Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. *Science* **235**, 880-884.

[82] Karch CM, Jeng AF, Nowotny P, Cady J, Cruchaga C, Goate AM (2012) Expression of novel Alzheimer’s disease risk genes in control and Alzheimer’s disease brains. *PLoS One* **7**, e50976.

[83] Bekris LM, Yu CE, Bird TD, Tsuang DW (2010) Genetics of Alzheimer disease. *J Geriatr Psychiatry Neurol* **23**, 213-227.

[84] Koo EH, Szuazzo SL (1994) Evidence that production and release of amyloid beta-protein involves the endocytic pathway. *J Biol Chem* **269**, 17386-17389.

[85] Bossy-Wetzel E, Schwarzenbacher R, Lipito SA (2004) Molecular pathways to neurodegeneration. *Nat Med* **10**, S2-S9.

[86] De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Gühde G, Annaert W, Von Figura K, Van Leuven F (1998) Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. *Nature* **391**, 387-390.

[87] Cruts M, Hendriks L, Van Broeckhoven C (1996) The presenilin genes: A new gene family involved in Alzheimer disease pathology. *Hum Mol Genet* **5**, 1449-1455.

[88] Baulac S, LaVoie MJ, Kimberly WT, Straule J, Wolfe MS, Selkoe DJ, Xia W (2003) Functional gamma-secretase complex assembly in Golgitrans-Golgi network: Interactions among presenilin, nicastrin, Aph1, Pen-2, and gamma-secretase substrates. *Neurobiol Dis* **14**, 194-204.

[89] De Strooper B (2003) Aph1, Pen-2, and Nicastrin with Presenilin generate an active gamma-secretase complex. *Neuron* **38**, 9-12.

[90] Kaminski WE, Orsó E, Diederich W, Klucken J, Drobnik W, Schmitz G (2000) Identification of a novel human sterol-sensitive ATP-binding cassette transporter (ABCA7). *Biochem Biophys Res Commun* **273**, 532-538.

[91] Broccardo C, Osorio J, Luciani MF, Schriml LM, Prades C, Shulenin I, Arnould T, Naudin L, Lafargue C, Rosier M, Jordan B, Denéfle P, Chimini G (2001) Comparative analysis of the promoter structure and genomic organization of the human and mouse ABCA7 gene encoding a novel ABCA7 transporter. *Cytogenet Cell Genet* **92**, 264-270.

[92] Ikeda Y, Abe-Dohmae S, Munehira Y, Aoki R, Kawamoto S, Furuya A, Shitara K, Amachi T, Kioka N, Matsuo M, Yokoyama S, Ueda K (2003) Posttranscriptional regulation of human ABCA7 and its function for the apoA-I-dependent lipid release. *Biochem Biophys Res Commun* **311**, 313-318.

[93] Jehle AW, Gardai SJ, Li S, Linsel-Nitschke P, Morimoto K, Janssen WJ, Vandivier RW, Wang N, Greenberg S, Dale BM, Qin C, Henson PM, Tall AR (2006) ATP-binding cassette transporter A7 enhances phagocytosis of apoptotic cells and associated ERK signaling in macrophages. *J Cell Biol* **174**, 547-556.

[94] Chan SL, Kim WS, Kwok JB, Hill AF, Cappai R, Rye KA, Garner B (2008) ATP-binding cassette transporter A7 regulates processing of amyloid precursor protein in vitro. *J Neurochem* **106**, 793-804.

[95] Lin JW, Wyszynski M, Madhavan R, Sealock R, Kim JU, Sheng M (1998) Yotiao, a novel protein of neuromuscular junction and brain that interacts with specific splice variants of NMDA receptor subunit NR1. *J Neurosci* **18**, 2017-2027.

[96] Westphal RS, Tavalin SJ, Lin JW, Alto NM, Fraser ID, Langeberg LK, Sheng M, Scott JD (1999) Regulation of human ABCA7 and its function for the apoA-I-dependent lipid release. *Biochem Biophys Res Commun* **263**, 69-77.

[97] Bossy-Wetzel E, Schwarzenbacher R, Lipito SA (2004) Molecular pathways to neurodegeneration. *Nat Med* **10**, S2-S9.

[98] De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Gühde G, Annaert W, Von Figura K, Van Leuven F (1998) Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. *Nature* **391**, 387-390.

[99] Cruts M, Hendriks L, Van Broeckhoven C (1996) The presenilin genes: A new gene family involved in Alzheimer disease pathology. *Hum Mol Genet* **5**, 1449-1455.

[100] Sakamuro D, Elliott KJ, Wechsler-Reya R, Prendergast GC (1996) BIN1 is a novel MYC-interacting protein with features of a tumor suppressor. *Nat Genet* **14**, 69-77.
[101] Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinstein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schärrmann B, Heun R, van den Bussche H, Heuser I, Kornhuber J, Wittfing J, Dichtmans G, Frölich L, Hampel H, Hüll M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Novotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingstone G, Bass NJ, Gurling H, McQuillun A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsohali M, Singleton A, Guerreiro R, Mühleisen TW, Nöthen MM, Moebus S, Jöckel KH, Knopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O’Donovan M, Owen MJ, Williams J (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. *Nat Genet.*, 41, 1088-1093.

[102] Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff-Radford NR, De Jager PL, Evans D, Schneider JA, Cruchaga C, Ertken-Taner N, Younkin SG, Cruchaga C, Kauwe JS, Novotny P, Kramer P, Hardy J, Huentelman MJ, Myers AJ, Barnarda MM, Demirci FY, Baldwin CT, Green RC, Rogocea E, St George-Hyslop P, Arnold SE, Barber R, Beach T, Bigio EH, Bowen JD, Boxer A, Burke JR, Cairns NJ, Carlson CS, Carney RM, Carroll SL, Chiu HC, Clark DG, Comeveaux J, Cotman CW, Cummings JL, DeCarli C, DeKosky ST, Diaz-Arrastia R, Dick M, Dickson DW, Ellis WJ, Faber KM, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearin M, Geschwinda DH, Ghetti B, Gilbert JR, Gilman S, Giordani B, Glass JD, Growdon JH, Hamilton JL, Harrell LE, Head E, Honig LS, Hulette CM, Hymant BT, Jicha GA, Jin LW, Johnson N, Karlavish J, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Lah JJ, Levey AI, Lieberburg I, Lorey J, Ludolph AC, Low WC, Machulda MM, Mahley RW, Manczak MA, Manly JI, Mayeux R, McDowell AN, McKee AC, Mesulam MM, Miller BL, Miller F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McGeer EL, McGeer PG, McGeer EJ, Mehta JS, Mejia-Gonzalez R, Mehta GS, Mempel T, Menke-Parrott A, Meuleman D, Mercken M, Merrill DA, Merrill DJ, Merrett M, Merz BG, Meredith PR, Mittal S, Mooseker MS, Moritz C, Moskowitz MA, Mucke L, Nalls MA, Nance ML, Neumann M, Niedernhofer LJ, Nitsch RD, Novak T, Nourmohammad F, Nurrish J, O’Brien JT, O’Donovan MC, Olanow CW, Olivero MF, Olesen JS, Olsen C, O’Sullivan G, Oussoren E, O’Dwyer SF, Paulson HL, Pavlides C, Peñalvo JL, Pericak-Vance MA, Petrella MA, Petersen RC, Poon WW, Quinn JF, Rajbhandary RA, Raskind MA, Reiman EM, Bennett DA, Morris JC, Montine TJ, Montine SK, Morishita R, Moscarello MA, Morin MA, Mucke L, Muchowski L, Multhaup G, Murphy GM, Murphy BC, Murphy ME, Mustata G, Naqvi S, Navon R, Nebesky W, Neumann M, Neumann M, Ninkovic J, Noone NM, Novac M, Nowotny P, Norris RM, Novin Delorak M, O’Donovan MR, O’Farrell PH, Olanow CW, Oler S, Osorio I, Osborne RC, Osorio I, Ousmane G, Papp LA, Parsadanian M, Park JS, Park IS, Park JS, Park IS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park JS, Park J
Shin RW, Iwaki T, Kitamoto T, Tateishi J (1991) Hydrated phospholipid bilayers inhibit microglial uptake of amyloid beta. *Neuron* 78, 631-643.

Simón AM, de Maturana RL, Ricobaraza A, Escribano L, Schiaparelli L, Cuadrado-Tejedor M, Pérez-Mediavilla A, Avila J, Del Río J, Frenchilla D (2009) Early changes in hippocampal Eph receptors precede the onset of memory decline in mouse models of Alzheimer's disease. *J Alzheimers Dis* 17, 773-786.

Rogaea E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, Katayama T, Baldwin CT, Cheng R, Hasegawa H, Chen F, Shibata N, Lunetta KL, Pardossi-Piquard R, Bohn C, Wakutani Y, Cupples LA, Cuenco KT, Green RC, Pinessi L, Rainero I, Sorbi S, Bruni A, Duara R, Friedland RP, Inzelberg R, Hampe W, Bujo H, Song YQ, Andersen OM, Willnow TE, Graff-Radford N, Petersen RC, Dickson D, Der SD, Fraser PE, Schmitt-Ulms G, Youngk S, Mayeux R, Furrer L, St George-Hyslop P (Genet) (2007) The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. *Nature* 39, 168-177.

Lee JH, Cheng R, Honig LS, Vonsattel JG, Clark L, Mayeux R (2008) Association between genetic variants in SORL1 and autopsy-confirmed Alzheimer disease. *Neurology* 70, 887-889.

Andersen OM, Reiche J, Schmidt V, Gotthardt M, Speolgen R, Behlke J, von Armin CA, Breiderhoff T, Jansen P, Wu X, Bales KR, Cappai R, Masters CL, Gliemann J, Mufson EJ, Hyman BT, Paul SM, Nykjaer A, Willnow TE (2005) Neuronal sorting protein-related receptor sorL1 regulates processing of the amyloid precursor protein. *Proc Natl Acad Sci USA* 102, 13461-13466.

Reitz C, Cheng R, Rogaea E, Lee JH, Tokuhiko S, Zou F, Bettens K, Sleeegers K, Tan EK, Kimura R, Shibata N, Arai H, Kamboh MI, Prince JA, Maier W, Riemen-schneider M, Owen M, Harold D, Hollingworth P, Cellini E, Sorbi S, Naemias B, Takeda M, Pericak-Vance MA, Haines JL, Youngk S, Williams J, van Broeckhoven C, Furrer L, St George-Hyslop PH, Mayeux R; Genetic and Environmental Risk in Alzheimer Disease1 Consor-tium (2011) Meta-analysis of the association between variants in SORL1 and Alzheimer disease. *Arch Neurol* 68, 99-106.

Rohn TT (2013) The triggering receptor expressed on myeloid cells 2: “TREM-ming” the inflammatory component associated with Alzheimer’s disease. *Oxid Med Cell Longev* 2013, 860959.

Colonna M (2003) TREMs in the immune system and beyond. *Nat Rev Immunol* 3, 445-453.

Buée L, Bussières T, Buée-Schenner V, Delacourte A, Hof PR (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. *Brain Res Brain Res Rev* 33, 95-130.

Pedersen JT, Sigurdsson EM (2015) Tau immunotherapy for Alzheimer’s disease. *Trends Mol Med* 21, 394-402.

Shin RW, Iwaki T, Kitamoto T, Tateishi J (1991) Hydrated autoclave pretreatment enhances tau immunoreactivity in formalin-fixed normal and Alzheimer’s disease brain tissues. *Lab Invest* 64, 693-702.

Hoozemans JJ, Veerhuis R, Van Haastert ES, Rozenmuller JM, Baas F, Eikelenboom P, Scheper W (2005) The unfolded protein response is activated in Alzheimer’s disease. *Acta Neuropathol* 110, 165-172.

López Salon M, Morelli L, Castaño EM, Soto EF, Pasquini JM (2000) Defective ubiquitination of cerebral proteins in Alzheimer’s disease. *J Neurosci Res* 62, 302-310.

Archangelos LF, Gläsner J, Krause A, Bohlander SK (2006) The novel CALM interactor CATS influences the sub-cellular localization of the leukemogenic fusion protein CALM/AF10. *Oncogene* 25, 4099-4109.

Morris MC, Tangney CC, Wang Y, Sacks FM, Barnes LL, Bennett DA, Aggarwal NT (2015) MIND diet slows cognitive decline with aging. *Alzheimers Dement* 11, 1015-1022.

Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR, Jr (2009) Alzheimer’s Disease Neuroimaging Initiative, MRI and CSF biomarkers in normal, MCI, and AD subjects: Diagnostic discrimination and cognitive correlations. *Neurology* 73, 287-293.

Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR, Jr, Alzheimer’s Disease Neuroimaging Initiative (2009) MRI and CSF biomarkers in normal, MCI, and AD subjects: Predicting future clinical change. *Neurology* 73, 294-301.

Zhang D, Wang Y, Zhou L, Yuan H, Shen D; Alzheimer’s Disease Neuroimaging Initiative (2011) Multimodal classification of Alzheimer’s disease and mild cognitive impairment. *Neuroimage* 55, 856-867.

McKhan GM, Albert MS, Sperling RA (2012) Changing diagnostic concepts of Alzheimer’s disease. In *Alzheimer’s disease- Modernizing concept, biological diagnosis and therapy*, Karger, Basel, Switzerland, pp. 115-121.

Bloudek LM, Spackman DE, Blankenburg M, Sullivan SD (2011) Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer’s disease. *J Alzheimers Dis* 26, 627-645.

Kumar A, Dogra S (2008) Neuropathology and therapeutic management of Alzheimer’s disease - An update. *Drugs* 33, 433-446.

Kurz A, Pernecky R (2011) Novel insights for the treatment of Alzheimer’s disease. *Prog Neuropsychopharmacol Biol Psychiatry* 35, 373-379.

Anand R, Gill KD, Mahdi AA (2014) Therapeutics of Alzheimer’s disease: Past, present and future. *Neuropsychopharmacology* 76, 27-50.

Selkoe DJ (2001) Alzheimer’s disease: Genes, proteins, and therapy. *Physiol Rev* 81, 741-766.

Querfurth HW, Laferla FM (2010) Alzheimer’s disease. *N Engl J Med* 362, 329-344.

Hardy J (2009) The amyloid hypothesis for Alzheimer’s disease: A critical reappraisal. *J Neurochem* 110, 1129-1134.

Dal Prà I, Chiarini A, Gui L, Chakravarthy B, Pacchiana R, McKhann GM, Albert MS, Sullivan SD (2011) Review and meta-analysis of biomarkers and diagnostic concepts of Alzheimer’s disease. In *Alzheimer’s disease: Modernizing concept, biological diagnosis and therapy*. Karger, Basel, Switzerland, pp. 115-121.

Bloudek LM, Spackman DE, Blankenburg M, Sullivan SD (2011) Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer’s disease. *J Alzheimers Dis* 26, 627-645.

Kumar A, Dogra S (2008) Neuropathology and therapeutic management of Alzheimer’s disease - An update. *Drugs* 33, 433-446.

Kurz A, Pernecky R (2011) Novel insights for the treatment of Alzheimer’s disease. *Prog Neuropsychopharmacol Biol Psychiatry* 35, 373-379.

Anand R, Gill KD, Mahdi AA (2014) Therapeutics of Alzheimer’s disease: Past, present and future. *Neuropsychopharmacology* 76, 27-50.

Selkoe DJ (2001) Alzheimer’s disease: Genes, proteins, and therapy. *Physiol Rev* 81, 741-766.

Querfurth HW, Laferla FM (2010) Alzheimer’s disease. *N Engl J Med* 362, 329-344.

Hardy J (2009) The amyloid hypothesis for Alzheimer’s disease: A critical reappraisal. *J Neurochem* 110, 1129-1134.

Dal Prà I, Chiarini A, Gui L, Chakravarthy B, Pacchiana R, Gardenal E, Whitfield JF, Armatto U (2015) Do astrocytes collaborate with neurons in spreading the “infectious” Aβ? And Tau drivers of Alzheimer’s disease? *Neuroscientist* 21, 9-29.

Galimberti D, Ghelzi L, Scarpini E (2013) Immunotherapy against amyloid pathology in Alzheimer’s disease. *J Neurol Sci* 333, 50-54.

Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. *Science* 297, 353-356.

Ghosh AK, Brindisi M, Tang J (2012) Developing β-secretase inhibitors for treatment of Alzheimer’s disease. *J Neurochem* 120, 71-83.
[151] Chang WP, Huang X, Downs D, Cerrito JR, Koelsch G, Holtzman DM, Ghosh AK, Tang J (2011) Beta-secretase inhibitor GRL-8234 rescues age related cognitive decline in APP transgenic mice. *EASEB J* 25, 775-784.

[152] Mitani Y, Yarimizu J, Saita K, Uchino H, Akashiba H, Shitaka Y, Ni K, Matsuoka N (2012) Differential effects between gamma secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. *J Neurosci* 32, 2037-2050.

[153] Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yaraske KE, Friedrich SW, Demattos RB, May PC, Paul SM, Holtzman DM (2009) A gamma secretase inhibitor decreases amyloid-beta production in the central nervous system. *Ann Neurol* 66, 48-54.

[154] Henley DB, May PC, Dean RA, Siemers ER (2009) Development of semagacestat (LY-450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer’s disease. *Exp Opin Pharmacother* 10, 1657-1664.

[155] Yesuvadian R, Krishnamoorthy J, Ramamoorthy A, Bhunia A (2014) Potent gamma-secretase inhibitors/modulators interact with amyloid-beta fibrils but do not inhibit fibrillation: A high-resolution NMR study. *Biochem Biophys Res Commun* 447, 590-595.

[156] Tomita T (2009) Secretase inhibitors and modulators for Alzheimer’s disease treatment. *Expert Rev Neurother* 9, 661-679.

[157] Griffiths HH, Morten IJ, Hooper NM (2008) Emerging and potential therapies for Alzheimer’s disease. *Expert Opin Ther Targets* 12, 693-704.

[158] Tang J, Xu H, Fan X, Li D, Rancourt D, Zhou G, Li Z, Yang L (2008) Embryonic stem cell-derived neural precursor cells improve memory dysfunction in Abeta(1-40) injured rats. *Neurosci Res* 62, 86-96.

[159] Zheng MQ, Yin DZ, Zhang L, Lei B, Cheng DF, Cai HC, Han YJ, Wu MX, Zhang H, Wang J (2008) Biological characters of [18F]O-FEt-PIB in a rat model of Alzheimer’s disease using micro-PET imaging. *Acta Pharmacol Sin* 29, 548-554.

[160] Han M, Feng Y, Sun YY (2010) Preparation of small molecule compounds for promoting stem cells hyperplasia. *PCT Int Appl* 41 pp. WO 2010130063, A1 20101118, CAN 153:643462.

[161] Hawkes CA, Ng V, McLaurin J (2009) Small molecule inhibitors of Aβ-aggregation and neurotoxicity. *Drug Dev Res* 70, 111-124.

[162] Seo JS, Kim TK, Leem YH, Lee KW, Park SK, Baek IS, Kim KS, Im GJ, Lee SM, Park YH, Han PL (2009) SK-PC-B70M confers anti-oxidant activity and reduces Abeta levels in the brain of Tg2576 mice. *Brain Res* 1261, 100-108.

[163] Liu G, Huang W, Moir RD, Vanderburg CR, Lai B, Peng Z, Tanzi RE, Rogers JT, Huang X (2006) Metal exposure and Alzheimer pathogenesis. *J Struct Biol* 155, 45-51.

[164] Kenche VB, Barnham KJ (2011) Alzheimer’s disease and metals: Therapeutic opportunities. *Br J Pharmacol* 163, 211-219.

[165] Crouch PJ, Barnham KJ (2012) Therapeutic redistribution of metal ions to treat Alzheimer’s disease. *Acc Chem Res* 45, 1604-1611.

[166] Belyaev ND, Nalivaeva NN, Makova NZ, Turner AJ (2009) Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: Implications for Alzheimer disease. *EMBO Rep* 10, 94-100.

[167] Lemere CA (2013) Immunotherapy for Alzheimer’s disease: Hoops and hurdles. *Mol Neurodegener* 8, 36.

[168] Wisniewski T, Goñi F (2014) Immunotherapy for Alzheimer’s disease. *Biochem Pharmacol* 88, 499-507.

[169] Nicoll JA, Wilkinson D, Holmes C, Stewart P, Markham H, Weller RO (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: A case report. *Nat Med* 9, 448-452.

[170] Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L, Schenk D (2005) Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. *Neurology* 64, 129-131.

[171] Ferrer I, Boada Rovira M, Sánchez Guerra ML, Rey MJ, Costa-Jussá F (2004) Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer’s disease. *Brain Pathol* 14, 11-20.

[172] Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM; AN1792(QS-21)-201 Study Team (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. *Neurology* 64, 1553-1562.

[173] Frazer ME, Hughes JE, Mastrangelo MA, Tibbens JL, Federeoff HJ, Bowers WJ (2008) Reduced pathology and improved behavioral performance in Alzheimer’s disease mice vaccinated with HSV amplicons expressing amyloid-beta and interleukin-4. *Mol Ther* 16, 845-853.

[174] Benedetti F, Bollettini I, Barberi I, Radaelli D, Poletti S, Locatelli C, Pirovano A, Lorenzi C, Falini A, Colombo C, Smeraldi E (2013) Lithium and GSK3-β promoter gene variants influence white matter microstructure in bipolar disorder. *Neuropsychopharmacology* 38, 313-327.

[175] Dill J, Wang H, Zhou F, Li S (2008) Inactivation of glycogen synthase kinase 3 promotes axonal growth and recovery in the CNS. *J Neurosci* 28, 8914-8928.

[176] Engel T, Gotti-Oliver P, Lucas JJ, Avila J, Hernández F (2006) Chronic lithium administration to FTDP-17 tau and GSK3-beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. *J Neurochem* 99, 1445-1455.

[177] Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, Gaynor K, Wang L, LaFrancois J, Feinstein B, Burns M, Krishnamurthy P, Wen Y, Bhat R, Lewis J, Dickson D, Duff K (2005) Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. *Proc Natl Acad Sci U S A* 102, 6990-6995.

[178] Hampel H, Ewers M, Bürger K, Annas P, Mörtberg A, Bogstedt A, Frölich L, Schröder J, Schönknecht P, Riepe MW, Kraft I, Gasser T, Leyhe T, Möller HJ, Kurz A, Basun H (2009) Lithium trial in Alzheimer’s disease: A randomized, single-blind, placebo-controlled, multicenter 10-week study. *J Clin Psychiatry* 70, 922-931.

[179] Selénica ML, Jensen HS, Larsen AK, Pedersen ML, Helboe L, Leist M, Lotharius J, Meworkia L (2007) Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation. *Br J Pharmacol* 152, 959-979.

[180] Hwang SH, Shin EJ, Shin TJ, Lee BH, Choi SH, Kang J, Kim HJ, Kwon SH, Jang CG, Lee JH, Kim HC, Nah SY (2012) Gintonin, a ginseng-derived lysophosphatic acid receptor ligand, attenuates Alzheimer’s disease-related neuropathies: Involvement of non-amyloidogenic processing. *J Alzheimers Dis* 31, 207-223.
[181] Chen F, Eckman EA, Eckman CB (2006) Reductions in levels of the Alzheimer’s amyloid beta peptide after oral administration of ginsenosides. FASEB J 20, 1269-1271.

[182] Tian X, Zhang L, Wang J, Dai J, Shen S, Yang L, Huang P (2013) The protective effect of hyperbaric oxygen and Ginkgo biloba extract on Aβ25-35-induced oxidative stress and neuronal apoptosis in rats. Behav Brain Res 242, 1-8.

[183] Luo Y, Smith JV, Paramasivam V, Burdick A, Curry KJ, Buford JP, Khan I, Netzer WJ, Xu H, Butko P (2002) Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci USA 99, 12197-12202.

[184] Le Bars PL, Velasco FM, Ferguson JM, Dessain EC, Kieser M, Hoerr R (2002) Influence of the severity of cognitive impairment on the effect of the Ginkgo biloba extract EGb 761 in Alzheimer’s disease. Neuropharmacology 45, 19-26.

[185] Kaboyama T, Tohda C, Komatsu K (2005) Neuritic regeneration and synaptic reconstruction induced by withanolide A. Br J Pharmacol 144, 961-971.

[186] Kurapati KR, Athuri VS, Samikkannu T, Nair MP (2013) Ashwagandha (Withania somnifera) reverses β-amyloid1-42 induced toxicity in human neuronal cells: Implications in HIV-Associated Neurocognitive Disorders (HAND). PLoS One 8, e77624.

[187] Lee WH, Loo CY, Bebawy M, Luk F, Mason RS, Rohanizadeh R (2013) Curcumin and its derivatives: Their application in neuropharmacology and neuroscience in the 21st century. Curr Neuropharmacol 11, 338-378.

[188] Cole GM, Teter B, Frautschy SA (2007) Neuroprotective effects of curcumin. Adv Exp Med Biol 595, 197-212.

[189] Daneschvili HL, Aronson MD, Smetana GW (2015) Do statins prevent Alzheimer’s disease? A narrative review. Euro J Intern Med 26, 666-669.

[190] Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD (2008) Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 71, 344-350.

[191] Sparks DL, Kryscio RJ, Sabagh MN, Connor DJ, Sparks LM, Liebsack C (2008) Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr Alzheimer Res 5, 416-421.

[192] Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM (2009) Statins are associated with a reduced risk of Alzheimer disease regardless of lipoplipidemia. The Rotterdam Study. J Neurol Neurosurg Psychiatry 80, 13-17.

[193] Swiger KJ, Manalac RJ, Blumenthal RS, Blaha MJ, Martin SS (2013) Statins and cognition: A systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clin Proc 88, 1213-1221.

[194] McGuinness B, Craig D, Bullock R, Passmore P (2009) Statins for the prevention of dementia. Cochrane Database Syst Rev 2, CD003160.

[195] Lezoualc’h F, Sparapani M, Behl C (1998) N-acetylserotonin (normelatonin) and melatonin protect neurons against oxidative challenges and suppress the activity of the transcription factor NF-kappaB. J Pineal Res 24, 168-178.

[196] Pappolla MA, Chyan YJ, Poeggeler B, Frangione B, Wilson G, Ghiso J, Reiter RJ (2000) An assessment of the antioxidant and antiangiogenic properties of melatonin: Implications for Alzheimer’s disease. J Neural Transm (Vienna) 107, 203-231.

[197] Deng YQ, Xu GG, Duan P, Zhang Q, Wang JZ (2005) Effects of melatonin on wortmannin-induced tau hyperphosphorylation. Acta Pharmacol Sin 26, 519-526.

[198] Vgenopoulou I, Katsa ME, Travella F (2015) Melatonin levels in Alzheimer disease. Int J Car Sci 8, 499-506.

[199] Mirsadeghi S, Dinarnvard R (2015) Can nanoparticles be beneficial for the early detection and treatment of Alzheimer disease. J Med Hypo Ideas 9, 86-87.

[200] Simmons-Stern NR, Budson AE, Ally BA (2010) Music as a memory enhancer in patients with Alzheimer’s disease. Neuropsychologia 48, 3164-3167.

[201] Simmons-Stern NR, Deason RG, Brandler B, Frustace BS, O’Connor MK, Ally BA, Budson AE (2012) Music-based memory enhancement in Alzheimer’s disease: Promise and limitations. Neuropsychologia 50, 3295-3303.

[202] Ueda T, Suzukamo Y, Sato M, Izumi S (2013) Effects of music therapy on behavioral and psychological symptoms of dementia: A systematic review and meta-analysis. Age Res Rev 12, 628-641.

[203] Rahman A, Salam F, Islam MA, Anwarullah AKM, Islam MR, Nurul M, Miah A, Saha UK, Ali Z (2012) Alzheimer’s disease – an update. Bangladesh J Neurosci 28, 52-58.

[204] Ng M, Freeman MK, Fleming TD, Robinson M, Dwyer-Lindgren L, Thomson B, Wollum A, Sanman E, Wulf S, Lopez AD, Murray CJ, Gakidou E (2014) Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA 311, 183-192.

[205] WHO. Global adult tobacco survey (GATS): Bangladesh. World Health Organization 2009. http://www.who.int/tobacco/surveillance/fact_sheet_gats_bangladesh_2009.pdf

[206] Global Tobacco Surveillance System. Global Adult Tobacco Survey – Bangladesh report 2009. Dhaka: World Health Organization, Country office for Bangladesh; 2009. http://www.searo.who.int/bangladesh/publications/gats_2009/en/

[207] Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, Mullan EC, Birdy SK, Ababat C, Abera SF, Abraham JP, Abu-Rmeileh NM, Achoki T, AlIBhairan FS, Alemu ZA, Alfonso R, Ali MK, Ali R, Guzman NA, Ammar W, Anvari P, Baraner A, Barquera S, Basu S, Bennett DA, Bluttza B, Blauzer J, Cabral N, Nonato IC, Chang JC, Choudhry R, Courville KJ, Criqui MH, Cun- diff DK, Dabhadkar KC, Dandonia L, Davis A, Dayama A, Dharmaratne SD, Ding EL, Dunnari AM, Esteghamati A, Farzadfar F, Fay DF, Feiglin VL, Flaxman A, Forouzanfar MH, Goto A, Green MA, Gupta R, Hafezi-Nejad N, Hankey GJ, Harewood HC, Havmoeller R, Hay S, Hernandez L, Husseini A, Idrisov BT, Ikeda N, Islami F, Jahangir E, Jassal SK, Jee SH, Jeffrey M, Jonas JB, Kabbagame EK, Khalifa SE, Kengne AP, Khader YS, Khan YH, Kim D, Kimokoti RW, Kinge JM, Kabuto Y, Kosen S, Kwan G, Lai T, Leinsalu M, Li Y, Liang X, Liu S, Logroscino G, Lotufo PA, Lu Y, Ma J, Mainoo NK, Mansal GA, Merriman TR, Mokdad AH, Moschandreas J, Nagihami N, Naheed A, Nand D, Narayan KM, Nelson EL, Neuhouser ML, Nisar MI, Ohkubo T, Oti SO, Pedroza A, Prabhakaran D, Dharmaratne SD, Ding EL, Dunnari AM, Esteghamati A, Farzadfar F, Fay DF, Feiglin VL, Flaxman A, Forouzanfar MH, Goto A, Green MA, Gupta R, Hafezi-Nejad N, Hankey GJ, Harewood HC, Havmoeller R, Hay S, Hernandez L, Husseini A, Idrisov BT, Ikeda N, Islami F, Jahangir E, Jassal SK, Jee SH, Jeffrey M, Jonas JB, Kabbagame EK, Khalifa SE, Kengne AP, Khader YS, Khan YH, Kim D, Kimokoti RW, Kinge JM, Kabuto Y, Kosen S, Kwan G, Lai T, Leinsalu M, Li Y, Liang X, Liu S, Logroscino G, Lotufo PA, Lu Y, Ma J, Mainoo NK, Mansal GA, Merriman TR, Mokdad AH, Moschandreas J, Nagihami N, Naheed A, Nand D, Narayan KM, Nelson EL, Neuhouser ML, Nisar MI, Ohkubo T, Oti SO, Pedroza A, Prabhakaran D, Roy N, Sampson U, Seo H, Seppanlu SG, Shibu A, Khamri K, Shire R, Shuie I, Singh GM, Singh JA, Skirbekk V, Stapelberg NR, Sturua L, Sykes BL, Tobias M, Tran BX, Trasole L, Toshimasa H, van de Vijver S, Vasankari T, Veerman JL, Velasquez-Melendez G, Vlassov VV, Volset SE, Vos T, Wang C, Wang X, Weiderpass E, Werdecker A, Wright JL, Yang YC, Yatsuya H, Yoon J, Yoon SJ,
Zhao Y, Zhou M, Zhu S, Lopez AD, Murray CJ, Gakidou E (2014) Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: A systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 384, 766-781.

Rahman S, Islam MT, Alam DS (2014) Obesity and overweight in Bangladeshi children and adolescents: A scoping review. *BMC Public Health* 14, 70.

[209] Imtiaz B, Tolppanen AM, Kivipelto M, Soininen H (2014) Future directions in Alzheimer’s disease from risk factors to prevention. *Biochem Pharmacol* 88, 661-670.

[210] Bullock R (2004) Future directions in the treatment of Alzheimer’s disease. *Expert Opin Investig Drugs* 13, 303-314.